Search research articles
Contact Us
Filters
Showing results (31-40 of 313) with videos related to
Page
of 32
Sort By:
Advances in Therapy
|
June 28, 2018
Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials
Ralph A DeFronzo, Christopher Lee, Sven Kohler
Current Diabetes Reports
|
July 16, 2008
Mitochondrial dysfunction, insulin resistance, and type 2 diabetes mellitus
Muhammad A Abdul-Ghani, Ralph A DeFronzo
Current Diabetes Reports
|
June 4, 2009
Pathophysiology of prediabetes
Muhammad A Abdul-Ghani, Ralph A DeFronzo
Expert Opinion on Pharmacotherapy
|
August 21, 2014
What are the pharmacotherapy options for treating prediabetes?
Giuseppe Daniele, Muhammad Abdul-Ghani, Ralph A DeFronzo
Current Opinion in Clinical Nutrition and Metabolic Care
|
July 9, 2016
Prediabetes and risk of diabetes and associated complications: impaired fasting glucose versus impaired glucose tolerance: does it matter?
Muhammad Abdul-Ghani, Ralph A DeFronzo, Amin Jayyousi
Diabetes, Obesity & Metabolism
|
June 17, 2026
How the First 9 Months Shape the Rest of Your Life: The Impact of Gestational Diabetes on the Metabolic Future
Mustafa Kanat, Muhammad Abdul-Ghani, Ralph A DeFronzo
Nature Reviews. Nephrology
|
December 13, 2016
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
Ralph A DeFronzo, Luke Norton, Muhammad Abdul-Ghani
Diabetes
|
August 28, 2012
Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?
Jiwen Jim Liu, TaeWeon Lee, Ralph A DeFronzo
Diabetes
|
October 20, 2020
Adaptation of Insulin Clearance to Metabolic Demand Is a Key Determinant of Glucose Tolerance
Amalia Gastaldelli, Muhammad Abdul Ghani, Ralph A DeFronzo
Nature Reviews. Nephrology
|
March 26, 2026
Insulin resistance and hyperinsulinaemia in kidney disease: mechanisms and metabolic effects
Hussein Zaitoon, Muhammad Abdul-Ghani, Ralph A DeFronzo
Page
of 32
Search research articles
Search
Showing results (31-40 of 313) with videos related to
Sort By:
Page
of 32
Advances in Therapy
|
June 28, 2018
Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials
Ralph A DeFronzo, Christopher Lee, Sven Kohler
Current Diabetes Reports
|
July 16, 2008
Mitochondrial dysfunction, insulin resistance, and type 2 diabetes mellitus
Muhammad A Abdul-Ghani, Ralph A DeFronzo
Current Diabetes Reports
|
June 4, 2009
Pathophysiology of prediabetes
Muhammad A Abdul-Ghani, Ralph A DeFronzo
Expert Opinion on Pharmacotherapy
|
August 21, 2014
What are the pharmacotherapy options for treating prediabetes?
Giuseppe Daniele, Muhammad Abdul-Ghani, Ralph A DeFronzo
Current Opinion in Clinical Nutrition and Metabolic Care
|
July 9, 2016
Prediabetes and risk of diabetes and associated complications: impaired fasting glucose versus impaired glucose tolerance: does it matter?
Muhammad Abdul-Ghani, Ralph A DeFronzo, Amin Jayyousi
Diabetes, Obesity & Metabolism
|
June 17, 2026
How the First 9 Months Shape the Rest of Your Life: The Impact of Gestational Diabetes on the Metabolic Future
Mustafa Kanat, Muhammad Abdul-Ghani, Ralph A DeFronzo
Nature Reviews. Nephrology
|
December 13, 2016
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
Ralph A DeFronzo, Luke Norton, Muhammad Abdul-Ghani
Diabetes
|
August 28, 2012
Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?
Jiwen Jim Liu, TaeWeon Lee, Ralph A DeFronzo
Diabetes
|
October 20, 2020
Adaptation of Insulin Clearance to Metabolic Demand Is a Key Determinant of Glucose Tolerance
Amalia Gastaldelli, Muhammad Abdul Ghani, Ralph A DeFronzo
Nature Reviews. Nephrology
|
March 26, 2026
Insulin resistance and hyperinsulinaemia in kidney disease: mechanisms and metabolic effects
Hussein Zaitoon, Muhammad Abdul-Ghani, Ralph A DeFronzo
Page
of 32